Add to a list

Suspension of trading

CARMAT Share Price Boerse Muenchen

CXT

FR0010907956

Medical Equipment, Supplies & Distribution

OTC Markets Traded

Real-time Boerse Muenchen 07:44:13 25/09/2025 BST			5-day change	1st Jan Change
0.0985 ^EUR	-0.51%		-.--%	-

09-01	CARMAT SAS Publishes Results Of EFICAS Clinical Study On Aeson Total Artificial Heart As Bridge-To-Transplant Therapy	CI
01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris

Analysts' recommendations: CARMAT

09/05/25	Carmat: Invest Securities raises target price
11/04/25	Carmat: Invest Securities still a buyer, but cuts TP
04/02/25	Carmat: Invest Securities slightly lowers its target
09/01/25	Carmat: Invest Securities upgrades to buy
09/01/25	Carmat: Oddo BHF reduces its price target

More recommendations

News in other languages: CARMAT

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

More news

Managers and Directors: CARMAT

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	31/08/2016
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	11/12/2018
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	31/03/2025

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	01/01/2017
Michael Mack BRD	Director/Board Member	79	19/04/2017

More insiders

Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	6.15M 6.92M 5.74M 5.23M 9.86M 665M 9.95M 69.42M 26.9M 340M 25.97M 25.41M 1.09B	P/E 2023	-3.09x	P/E 2024	-0.95x
Enterprise Value	59.25M 66.68M 55.3M 50.4M 95.06M 6.41B 95.94M 669M 259M 3.28B 250M 245M 10.52B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

09-01	CARMAT SAS Publishes Results Of EFICAS Clinical Study On Aeson Total Artificial Heart As Bridge-To-Transplant Therapy	CI
01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-06	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-06	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-04	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
15/10/25	CAC 40 Surges on LVMH Results and Easing US-China Tensions
15/10/25	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
15/10/25	Carmat says liquidation review postponed until Nov 25	RE
01/10/25	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-04	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
29/10/25	CARMAT : Inside Information / Other news releases	PU
29/10/25	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
15/10/25	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-0.51%	-.--%	-	-	7.08M
ABBOTT LABORATORIES	+0.84%	-3.74%	-27.56%	+1.93%	169B
MEDTRONIC PLC	-0.07%	-2.55%	-11.59%	+13.26%	110B
STRYKER CORPORATION	+0.90%	+1.13%	-25.66%	+3.47%	106B
ESSILORLUXOTTICA	-1.24%	-0.76%	-49.50%	-12.46%	73.87B
CENCORA, INC.	-0.24%	+0.69%	+2.08%	+69.19%	58.98B
HOYA CORPORATION	+1.72%	+4.09%	+8.82%	+62.24%	51.28B
BECTON, DICKINSON AND COMPANY	-0.71%	-3.82%	-8.68%	-31.93%	48.16B
IDEXX LABORATORIES, INC.	+0.12%	-0.17%	-17.87%	+19.66%	40.84B
DEXCOM, INC.	-1.01%	-1.45%	+27.31%	-2.67%	32.21B
Average	-0.04%	-0.86%	-11.41%	+13.63%	76.69B
Weighted average by Cap.	+0.20%	-1.30%	-17.37%	+11.14%

	2023	2024
Net sales	3.84M 4.32M 3.58M 3.26M 6.16M 415M 6.21M 43.34M 16.79M 212M 16.21M 15.86M 681M	7.34M 8.27M 6.85M 6.25M 11.78M 795M 11.89M 82.95M 32.14M 406M 31.03M 30.36M 1.3B
Net income	-53.87M -60.63M -50.28M -45.83M -86.43M -5.83B -87.23M -608M -236M -2.98B -228M -223M -9.56B	-51.4M -57.84M -47.97M -43.72M -82.46M -5.56B -83.23M -581M -225M -2.84B -217M -212M -9.12B
Net Debt	49.64M 55.86M 46.33M 42.23M 79.64M 5.37B 80.38M 561M 217M 2.75B 210M 205M 8.81B	53.1M 59.76M 49.56M 45.17M 85.19M 5.75B 85.99M 600M 232M 2.94B 224M 220M 9.43B

CARMAT Share Price Boerse Muenchen

Stocks

CXT

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation: CARMAT

Latest news: CARMAT

Analysts' recommendations: CARMAT

Press Releases: CARMAT

News in other languages: CARMAT

Quotes and Performance

Managers and Directors: CARMAT

Medical Devices & Implants

Financials

Company Profile